Nontuberculous mycobacterial (NTM) pulmonary disease is a chronic respiratory infection
associated with declining lung function, radiological deterioration and significantly increased …

The management of difficult-to-treat acute and chronic respiratory infections (infections in
cystic fibrosis, non-cystic fibrosis bronchiectasis, immunocompromised and mechanically …

Aim The present study was conducted to formulate and investigate liposomes for the dual
drug delivery based on anti-tubercular drug (s) combination ie Isoniazid (INH) and …

An overview of current data on pulmonary delivery of liposomes is provided, entailing fate of
aerosols in the respiratory tract, physicochemical characterization of liposome aerosols, their …

The recent development of liposomal formulations compatible with aerosol delivery has
expanded the potential to utilise chemotherapeutic agents directly targeted to the lungs …

Liposomes are established drug carriers for inhalation owing to their biocompatibility,
biodegradability, and ability to entrap drugs and prolong their therapeutic effects in the …

Inhalation delivery of liposomal drugs has distinct advantages for the treatment of pulmonary
diseases. Inhalable liposomes of several drugs are currently undergoing clinical trials for a …

Liposomes have been widely used in pulmonary drug delivery for multiple applications
including solubilization, sustained release, cellular and intracellular targeting, minimization …

Liposomes are established drug carriers for inhalation owing to their safety and ability to
provide controlled drug release in the lung. These carriers can entrap a wide range of …

Non-tuberculous mycobacteria (NTM) cause pulmonary infections in patients with structural
lung damage, impaired immunity, or other risk factors. Delivering antibiotics to the sites of …